Next 10 |
2024-02-29 12:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting PR Newswire -- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable...
2024-02-20 12:17:26 ET Summary Blueprint Medicines' Ayvakit shows strong performance in the ISM market, with revenue projections increased to $2 billion. Q4 '23 earnings highlight significant growth, with Ayvakit driving revenues up and a strong cash position despite a high burn r...
Shares of Blueprint Medicines Corporation (NASDAQ: BPMC) traded at a new 52-week high today and are currently trading at $90.05. So far today, approximately 436.14k shares have been exchanged, as compared to an average 30-day volume of 872.33k shares. Blueprint Medicines Corporation, a precis...
2024-02-15 13:11:04 ET Blueprint Medicines Corporation (BPMC) Q4 2023 Earnings Conference Call February 15, 2024 08:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commerci...
2024-02-15 07:10:28 ET More on Blueprint Medicines Blueprint Medicines: Looking Toppy Blueprint Medicines Q4 2023 Earnings Preview Barron’s cites cancer and weight loss plays for biotech M&A Seeking Alpha’s Quant Rating on Blueprint Medicine...
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results PR Newswire -- Achieved $204.2 million in AYVAKIT ® /AYVAKYT ® (avapritinib) net product revenues in 2023, including $71.0 million in the fourth quarter -- -- Anti...
Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...
2024-02-14 15:30:47 ET Summary Cogent Biosciences, Inc. has entered into a securities purchase agreement for a private investment in public equity financing, expected to raise approximately $225 million. The financing was led by Commodore Capital and a large investment management ...
2024-02-14 14:07:39 ET More on Blueprint Medicines Blueprint Medicines: Looking Toppy Barron’s cites cancer and weight loss plays for biotech M&A Seeking Alpha’s Quant Rating on Blueprint Medicines Historical earnings data for Blueprint Medi...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
CAMBRIDGE, Mass., March 6, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), today announced that, effective March 1, 2024, the C...
2024-02-29 12:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting PR Newswire -- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable...